Remibrutinib

Published

dm+d

Unassigned

New Medicines

Chronic spontaneous urticaria

Information

New molecular entity
Novartis
Novartis

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Highly selective, potent Brutons tyrosine kinase (BTK) inhibitor for oral administration [1,2]
The lifetime prevalence of chronic urticaria in the UK is 0.5–1%, but approximately 15% of people experience urticaria at some time in their lives [4].
Chronic spontaneous urticaria
Oral